A truncated and modified Serratiopeptidase or a variant thereof, and polynucleotides encoding the same. The truncated and modified Serratiopeptidase may have an amino acid sequence including amino acids 1 to 344, and amino acids 1 to 380 of SEQ ID NO: 1. The truncated and modified Serratiopeptidase may further include a first Cysteine (C) residue at a N-terminus of the truncated and modified Serratiopeptidase, substituted for at least one of Alanine 8 and Leucine 12 of SEQ ID NO: 1; and a second Cysteine residue at a C-terminus of the truncated and modified Serratiopeptidase, substituted for at least one of Valine 339 and Arginine 302 of SEQ ID NO: 1. The first and the second Cysteine residues may be adapted to form at least one disulfide bond including at least one of C8-C339, and C12-C302 disulfide bonds between the N-terminus and the C-terminus of the truncated and modified Serratiopeptidase.

Methods are provided for treatment of wounds using a complex antimicrobial sorption composition possessing the necrolytic effect for treating the purulent wounds, the trophic ulcers, the wounds, and the infiltrates with the significant necrotic and exudative components represents the silica sorbent with the immobilized drug. Pyrogenic silica is used as a siliceous sorbent, and serrathiopeptidase as a drug.

Methods and compositions for treating cancer in a patient in need thereof are provided. The methods comprise administering an interferon or an extract containing the interferon, an immune promoting agent and a digestive enzyme to the patient. The interferon can comprise withaferin A; the immune promoting agent can comprise vitamins and the digestive enzyme can comprise serratiopeptidase.

An oral fibrinolytic composition comprising the enzymes serrapeptase and nattokinase. The composition treats and/or may prevent fibrosis conditions and their related symptoms in animals, including humans. This composition may further comprise of one or more enzymes, bioflavonoids, vitamins, coenzymes, minerals, probiotics, prebiotics, herbs, excipients and/or combinations thereof. The composition may improve lung capacity, oxygen saturation, vigor, and/or lung function. It may further alleviate dyspnea, limitations and fear caused by dyspnea, cough, phlegm, fatigue, body pain, chest discomfort, anxiety, depression, loss of appetite, and/or respiratory disorders. The composition of serrapeptase and nattokinase and/or one or more additional component may improve immune health, sleep, health-related quality of life (HRQoL), social well-being, health status, mental health and/or exercise capacity. The present disclosure also provides a method for improving or reducing the frequency and severity of fibrosis and related symptoms in a subject having a fibrotic disease.

The present invention relates to method of treating infectious disease, wherein treatment comprises administration of Serratiopeptidase, Mannose or isomers, salts, other derivatives thereof, and one or more antiinfection agents, in same or different compositions to humans or animals. The present invention relates to pharmaceutical composition comprising Serratiopeptidase and Mannose or isomers, salts, other derivatives thereof. The present invention relates to a pharmaceutical composition comprising Serratiopeptidase, Mannose or isomers, salts, other derivatives thereof, and one or more antiinfection agents.

A truncated and modified Serratiopeptidase or a variant thereof, and polynucleotides encoding the same. The truncated and modified Serratiopeptidase may have an amino acid sequence including amino acids 1 to 344, and amino acids 1 to 380 of SEQ ID NO: 1. The truncated and modified Serratiopeptidase may further include a first Cysteine (C) residue at a N-terminus of the truncated and modified Serratiopeptidase, substituted for at least one of Alanine 8 and Leucine 12 of SEQ ID NO: 1; and a second Cysteine residue at a C-terminus of the truncated and modified Serratiopeptidase, substituted for at least one of Valine 339 and Arginine 302 of SEQ ID NO: 1. The first and the second Cysteine residues may be adapted to form at least one disulfide bond including at least one of C8-C339, and C12-C302 disulfide bonds between the N-terminus and the C-terminus of the truncated and modified Serratiopeptidase.

Described herein are formulations that can include one or more enzymes that can break down one or more components of scar tissue. Also provided herein are methods of treating scar tissue by administering a formulation provided herein to a subject in need thereof.

Provided is an alkaline protease mutant with improved stability to a chelating agent. An alkaline protease mutant, in which an amino acid residue at a position corresponding to position 294 of the amino acid sequence as shown in SEQ ID NO: 2 is substituted in the amino acid sequence as shown in SEQ ID NO: 2, or an amino acid sequence having an identity of at least 95% thereto.

The present invention relates to methods for preventing, removing, reducing, or disrupting biofilm present on a surface, comprising contacting the surface with an alpha-amylase derived from a bacterium.

The present invention relates to methods for preventing, removing, reducing, or disrupting biofilm present on a surface, comprising contacting the surface with an alpha-amylase derived from a bacterium.